Endometriosis and antimüllerian hormone: future research directions & clinical implications (reply to letter to the editor)

Michelle Valenti, Leslie V. Farland
American journal of obstetrics and gynecology · 2026 · vol. 235(2) , pp. e63 · doi:10.1016/j.ajog.2026.03.020 · PMID:41903876
other OA: closed public-domain-us
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-29 ⓘ

This paper discusses future research directions and clinical implications regarding endometriosis and anti-Müllerian hormone in response to a letter to the editor.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-08-20T06:14:21.026120+00:00
pubmed
last seen: 2026-08-20T06:09:24.770180+00:00
unpaywall
last seen: 2026-05-11T08:34:28.763810+00:00
License: public-domain-us · commercial use OK · attribution required
Courtesy of the U.S. National Library of Medicine